Pediatr. praxi. 2014;15(6):340-343

Therapeutic strategies in cystic fibrosis

MUDr.Veronika Skalická
Centrum cystické fibrózy
Pediatrická klinika 2. LF UK a FN Motol, Praha

Cystic fibrosis (CF) is the most common autosomal recessive disease of the Caucasian population characterised by chronic multi-organ impairment.

Although cystic fibrosis is still incurable condition, it has been shown that holistic approach to treatment that is based on multi-professional

centre care provided by trained and experienced health professionals is necessary for optimal management and improved quality of life and

survival of patients. Complex treatment focused on intensive airway clearance, good nutritional status, aggressive anti-infective and anti-inflammatory

therapy and continuous search for complications is essential. New therapeutic strategies for CF focus on protein targeted treatment

of impaired cystic fibrosis transmembrane conductance regulator (CFTR) that is responsible for exocrine secretion pathology.

Keywords: cystic fibrosis, diagnosis, standards of care, treatment, CFTR potentiators and correctors, ivacaftor

Published: December 16, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skalická V. Therapeutic strategies in cystic fibrosis. Pediatr. praxi. 2014;15(6):340-343.
Download citation

References

  1. Český registr cystické fibrózy dostupný na www.cfregistr.cz.
  2. Vávrová V. a kol. Cystická fibróza. Praha: Grada, 2005: 520.
  3. Dřevínek P. Kauzální terapie cystické fibrózy. Postgraduální medicína 2014; 16(1): 21-22.
  4. Krulišová V, Balaščaková M, Skalická V, et al. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/ PAP and IRT/PAP/DNA. Eur J Pediatr 2012; 171(8): 1223-1229. Go to original source... Go to PubMed...
  5. Skalická V. Nové dimenze v diagnostice a léčbě cystické fibrózy: od novorozeneckého screeningu k léčbě podstaty onemocnění. Vox Pediatriae 2012; 12(3): 26-29.
  6. Votava F, Kožich V, Chrastina P, et al. Výsledky rozšířeného novorozeneckého screeningu v České republice. Čes-slov Pediat 2014; 69(2): 77-86.
  7. Conway S, Balfour-Lynn IM, De Rijcke K, et al. European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. Journal of Cystic Fibrosis 2014; 13(1): 3-22. Go to original source... Go to PubMed...
  8. Zemková D, Skalická V, Bartošová J. et al. Moderní management cystické fibrózy a jeho vliv na zdravotní stav a přežívání českých nemocných. Čes-slov Pediat 2008; 2: 76-82.
  9. Pryor JA, Prasad SA. Physiotherapy for Respiratory and Cardiac Problems. 4th edition London: Churchill Livingstone: 2009: 632.
  10. Smolíková L, Máček M. Respirační fyzioterapie a plicní rehabilitace. Brno: Národní centrum ošetřovatelství a nelékařských zdravotnických oborů 2010: 194.
  11. Skalická V, Koloušková S. Výživa u cystické fibrózy. In: Nevoral J. Praktická pediatrická gastroenterologie, hepatologie a výživa. Praha: Mladá fronta, 2013: 599-618.
  12. Munck A. Nutritional considerations in patients with cystic fibrosis. Expert Rev Respir Med. 2010; 4(1): 47-56. Go to original source... Go to PubMed...
  13. Döring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. Journal of Cystic Fibrosis 2012; 11(6): 461-479. Go to original source... Go to PubMed...
  14. Koloušková S, Zemková D, Bartošová J, et al. Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study. J Pediatr Endocrinol Metab. 2011, 24(7-8): 449-454. Go to original source... Go to PubMed...
  15. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007; 13(6): 529-536. Go to original source... Go to PubMed...
  16. Ramsey BW, Davies J, McElvaney NG et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365(18): 1663-1672. Go to original source... Go to PubMed...
  17. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187: 1219-1225. Go to original source... Go to PubMed...
  18. Vertex Current Press Releases. Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation. Vertex Media [online]. Jun 24, 2014. Dostupný na WWW: http://investors.vrtx.com/releases.cfm.
  19. Wilschanski M, Miller LL., Shoseyov D et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 38: 59-69. Go to original source... Go to PubMed...
  20. Burney TJ., Davies JC. Gene therapy for the treatment of cystic fibrosis. Appl Clin Genet 2012; 5: 29-36. Go to original source...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.